Board of Directors

David Mott

Chairman of the Board
General Partner, New Enterprise Associates, Inc.

David M. Mott joined New Enterprise Associates (NEA) in September 2008 as a General Partner focused on biopharmaceutical investments. Prior to joining NEA, he was President and Chief Executive Officer of MedImmune, a subsidiary of AstraZeneca Plc, and Executive Vice President of AstraZeneca. Mr. Mott joined MedImmune in 1992 and served in roles of increasing responsibility including Chief Operating Officer, Chief Financial Officer, President and Chief Executive Officer as the company grew from a venture-backed startup (founded in 1988) into one of the top five biotechnology companies in the world.

Ultimately, Mr. Mott initiated and executed the sale of MedImmune to AstraZeneca in June 2007 for $15.6 billion. In 2002, he founded MedImmune Ventures and chaired its investment committee through his departure from MedImmune. At the time of his departure in July 2008, MedImmune had annual revenues in excess of $1.5 billion, annual R&D in excess of $650 million and approximately 3,000 employees. Prior to joining MedImmune, Mr. Mott was a Vice President in the Health Care Investment Banking Group at Smith Barney, Harris Upham & Co. Inc. At Smith Barney, his activities included public and private equity and debt financings as well as merger and acquisition work for biotechnology, healthcare services, and medical product and device companies.

Mr. Mott is currently Chairman of 3-V Biosciences and Zyngenia, and is a director of Ardelyx, Epizyme, TESARO, and Zosano Pharma. He serves on the Advisory Board of the Scripps Translational Science Institute and the Governing Board of St. Albans School.

Jason Fuller, PhD

Mr. Fuller joined NEA as a Principal in 2014 and focuses on investments in biopharmaceuticals. Prior to joining NEA, he was a Principal with Third Rock Ventures where he contributed to the creation and management of several companies, including NinePoint Medical, Kala Pharmaceuticals and most recently, Jounce Therapeutics where he served as Director of Corporate development after helping found the company. Mr. Fuller earned his PhD at MIT under the supervision of Robert Langer as an NSF fellow, and received an MPhil from the University of Cambridge where he was a Churchill Scholar. He also holds a BS in Chemical Engineering from Michigan State University.

Gordon Ringold, PhD

Chairman and CEO, Alavita Pharmaceuticals, Inc.
Director for Silicon Valley Initiatives, UC Santa Cruz

Dr. Ringold is currently the Director for Silicon Valley Initiatives, UC Santa Cruz, and Executive Chairman of Alavita Pharmaceuticals. He is a co-founder and Director of Maxygen and Alexza Corporations and Managing Partner of Technogen Associates, L.P., a private investment firm. Dr. Ringold has more than 25 years of experience managing the discovery and development of pharmaceuticals and novel, enabling life science technologies. From 1997 to 2005, he served as Chairman and CEO of SurroMed, Inc., a biotechnology company focused on biomarker discovery technologies. From 1995 to 2000, Dr. Ringold was the CEO of the Glaxo-Wellcome Group’s Affymax Research Institute, where he managed the development of novel technologies to accelerate the pace of drug discovery. Before serving as CEO, Dr. Ringold was the President and Scientific Director of Affymax where he was instrumental in nurturing the development of the DNA shuffling technology and interacting with key parties to establish Maxygen. Prior to Affymax, Dr. Ringold served as the Director and Vice President of the Institute for Cancer and Development Biology at Syntex, now a division of Hoffman La-Roche.

Dr. Ringold received his BA and BS in Biology from University of California, Santa Cruz, and his PhD in Microbiology from University of California, San Francisco in the laboratory of Dr. Harold Varmus. He was on the faculty of the Department of Pharmacology at the Stanford University School of Medicine from 1978 to 1987.

Beth Seidenberg, MD

Partner, Kleiner Perkins Caulfield & Byers

Dr. Seidenberg joined Kleiner Perkins Caufield & Byers (KPCB) in May 2005 to work in the life sciences area. For the past 20 years, she has focused her career on introducing new innovative treatments for AIDS, arthritis, asthma, cancer, psoriasis, cardiovascular, metabolic, neurological and renal disorders. She introduced 10 innovative products to market and achieved over 40 regulatory approvals (including new indications and formulations) on a worldwide basis. These products have been successfully commercialized and have provided benefits to millions of patients with grievous illnesses and have generated several billion dollars of revenue.

Prior to joining KPCB, Dr. Seidenberg was Senior Vice President, Global Development, and Chief Medical Officer at Amgen, Inc., the world’s largest biotechnology company. During her three years there, Dr. Seidenberg’s responsibilities included all stages of clinical research, regulatory affairs, safety, health economics/ reimbursement and medical affairs. Prior to joining Amgen, Dr. Seidenberg was a senior executive in research and development at Bristol-Myers Squibb Company and Merck & Co., Inc. She began her career in basic and clinical research at the National Institutes of Health specializing in immunology and infectious diseases.

Dr. Seidenberg received her BS from Barnard College magna cum laude, Phi Beta Kappa; and her medical degree from the University of Miami School of Medicine, alpha omega alpha. Her post-graduate training was completed at Johns Hopkins, George Washington School of Medicine and the National Institutes of Health.

James F. Young, PhD

In addition to his Board seat with Sagimet Biosciences, Dr. Young currently serves on the Board of Directors of Novavax, Inc., and on the Board of Trustees of The Phillips Collection Museum of Modern Art in Washington, DC.  Recently, Dr. Young graduated first in his class with a Certificate de Cuisine from Le Cordon Bleu Academie d’Art Culinaire de Paris in Paris, France. Previously, he was with MedImmune, Inc. from 1988 through 2008 following its sale to AstraZeneca PLC. Dr. Young led MedImmune’s research and development organization and was directly involved in the development of approximately 20 clinical programs and the commercialization of Synagis9® , RespiGam®, CytoGam®, Flumist®, and Ethyol®. Prior to MedImmune, he was a Director in the Department of Molecular Genetics at Smith Kline and French Laboratories. Dr. Young has served on the Boards of Directors of Xencor, Inc., Iomai, Inc., and Arriva Pharmaceuticals, Inc. He received his PhD in Microbiology and Immunology from Baylor College of Medicine.

Merdad Parsey, MD, PhD

Dr. Parsey joined Sagimet Biosciences (then 3-V) as its President and Chief Executive Officer in September 2010. Prior to joining the Company, Dr. Parsey held positions of increasing responsibility at Genentech, Inc., a member of the Roche Group, most recently as Senior Group Medical Director in Genentech Research and Early Development, overseeing early clinical development in multiple therapeutic areas. Prior to Dr. Parsey’s tenure with Genentech, he was with Sepracor, Regeneron and Merck, Inc. He has worked on multiple development and post-marketing programs from initial human trials to NDA/BLA submissions in respiratory, inflammation, virology, neurology, ophthalmology and gastrointestinal diseases. In addition to his work in the biotechnology and pharmaceutical industries, Dr. Parsey was the Director of Critical Care Medicine at the NYU School of Medicine. He completed his MD and PhD at the University of Maryland, his residency in Internal Medicine at Stanford University and his fellowship in Pulmonary and Critical Care Medicine at the University of Colorado.

George Kemble, PhD


Dr. Kemble joined Sagimet Biosciences (then known as 3-V) in August 2011 as its Chief Scientific Officer and was promoted to Chief Executive Officer in October 2015. As CSO, Dr. Kemble was responsible for directing the medicinal chemistry, research, translational and CMC groups of 3-V and worked on several programs including the lead product candidate, TVB-2640 for oncology. Prior to joining the Company, Dr. Kemble served as the Senior Vice President of R&D and Head of Research at MedImmune, Inc., a subsidiary of Astra-Zeneca PLC. During his tenure, he was responsible for a large group of scientists dedicated to the research and development of programs across a number of therapeutic areas, including the launch of FluMist®, the first innovation in influenza vaccines in over 60 years. Dr. Kemble received a BS from the University of Santa Clara and a PhD from Stanford University and did his post-doctoral training at UCSF, where he worked on a number of different human viruses.

Richard Rodgers

In addition to his board seat with Sagimet Biosciences, Mr. Rodgers currently serves on the Board of Directors of Ardelyx, Inc. and Rexahn Pharmaceuticals, Inc. Previously, he was the Executive Vice President, Chief Financial Officer, Secretary and Treasurer of TESARO, an oncology focused biopharmaceutical company which he co-founded in March 2010. Mr. Rogers served as the Chief Financial Officer from June 2009 to February 2010 of Abraxis BioScience, which was subsequently acquired by Celgene. Prior to that, Mr. Rodgers served as Senior Vice President, Controller and Chief Accounting Officer of MGI PHARMA from 2004 until its acquisition by Eisai in January 2008. He has held finance and accounting positions at several private and public companies, including Arthur Anderson. Mr. Rodgers received a BS in Financial Accounting from St. Cloud State University and his MBA in Finance from the University of Minnesota, Carlson School of Business.

Jinzi J. Wu

Dr. Wu is Founder, Chairman and CEO of Ascletis, an innovative R&D-driven biotech with two commercial products that was founded in April 2013. Led by Dr. Wu, Ascletis (1672.HK) became the first pre-revenue biotech listed on the Hong Kong Stock Exchange in August 2018 and raised US$400M. Under his leadership, Ascletis has developed a fully integrated platform covering the entire value chain from discovery and development to manufacturing and commercialization. Also under his leadership, Ganovo® (Danoprevir), Ascletis’ first direct-acting antiviral agent (DAA) for hepatitis C, was successfully launched in June 2018 and is now commercialized by the Company’s 150+ member commercial team. Dr. Wu and his team filed an NDA in August 2018 for Ravidasvir, Ascletis’ second DAA for hepatitis C with best-in-class characteristics. Ascletis has built an innovative R&D pipeline focusing on viral, cancer and fatty liver diseases and consisting of antibody-based immunotherapy, first/best-in-class small molecules and siRNA at various clinical development stages. 

Dr. Wu has more than 20 years of experience covering R&D, GMP manufacturing and commercialization in big pharma and biotech. Prior to founding Ascletis, he was the Vice President at GSK R&D in the U.S. He has also held various R&D positions from Sr. Scientist to Vice President at Novartis, Immunex/Amgen and Ambrilia in USA and Canada. Dr. Wu obtained his PhD in Cancer Biology from University of Arizona.

Xufang Duan

Xufang Duan, MD, PhD, has served as the executive director of Qianhai Fund of Funds, a limited liability partnership fund of funds focused on high-tech and high-growth fields, since August 2016. From 2010 until 2016, she worked at Shenzhen Capital Group (SCGC), a venture capital firm founded by the Shenzhen Municipal Government in August 1999, where she has primarily focused on healthcare investing. Dr. Duan received a medical degree from Shanxi Medical University and a PhD in biochemistry from Shanghai Jiao Tong University School of Medicine. She completed her post-graduate training of business administration at South China University of Technology. Dr. Duan serves on the boards of directors/supervisors of several privately-held healthcare companies and venture capital funds, including Guangzhou Kangrui Biological Pharmaceutical Technology Co., Ltd., Lu Daopei Medical Group and C-Bridge Capital.